Drug Trial Radar · NCT04187495
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Jan 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 16, 2019
Primary completion
Dec 1, 2022
Study completion Dec 1, 2022
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with Relapsed or Refractory AML.
Conditions
- AML
Interventions
MAX-40279-01Drug
Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria. Part 2: Dose expansion, Recommended doses from Part 1. For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: 8 weeks
- Maximum tolerated dose (MTD)Time frame: 4 weeks
- Phase II dose (RP2D)Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.